Treatment optimization: an outline for future success

被引:5
作者
Flexner, Charles [1 ,2 ]
Plumley, Ben [3 ]
Ripin, David H. Brown [4 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Pangaea Global AIDS Fdn, Oakland, CA USA
[4] Clinton Hlth Access Initiat, Boston, MA USA
关键词
antiretroviral therapy; Conference on Antiretroviral Drug Optimization; fixed-dose combinations; regimen simplification; universal access; ANTIRETROVIRAL-NAIVE; HIV; PHARMACOKINETICS; DOLUTEGRAVIR; PREVENTION; INHIBITOR; SAFETY; ADULTS;
D O I
10.1097/COH.0000000000000003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewIn this issue of Current Opinion, the Guest Editors and their colleagues provide a comprehensive overview of current activities aimed at optimizing global HIV treatment. In this introduction, we outline current goals and approaches that will be described in more detail elsewhere in this issue.Recent findingsTwo recent conferences, the first and second Conference on Antiretroviral Drug Optimization (CADO), brought together experts from academia, governments, foundations, the pharmaceutical industry, and community activists to develop a global HIV-treatment research agenda for the coming decade focused on better therapies and how to make them accessible to a broader population of people living with HIV. Important recommendations included a focus on more efficient process chemistry for antiretroviral drugs, investigation of antiretroviral dose reduction as a possible optimization strategy, recognition of the increasing importance of concurrent infections and comorbidities especially tuberculosis and aging-related diseases, and identifying a highly effective and affordable nontoxic, once-daily fixed-dose combination regimen for first-line treatment.SummaryHIV treatment optimization is a process intended to enhance the long-term efficacy, adherence, tolerability, safety, convenience, and affordability of combination ART. The ultimate goal of this process is to expand access to well tolerated and effective lifetime treatment to all those in need.
引用
收藏
页码:523 / 527
页数:5
相关论文
共 13 条
[1]   Prevention of HIV-1 Infection with Early Antiretroviral Therapy [J].
Cohen, Myron S. ;
Chen, Ying Q. ;
McCauley, Marybeth ;
Gamble, Theresa ;
Hosseinipour, Mina C. ;
Kumarasamy, Nagalingeswaran ;
Hakim, James G. ;
Kumwenda, Johnstone ;
Grinsztejn, Beatriz ;
Pilotto, Jose H. S. ;
Godbole, Sheela V. ;
Mehendale, Sanjay ;
Chariyalertsak, Suwat ;
Santos, Breno R. ;
Mayer, Kenneth H. ;
Hoffman, Irving F. ;
Eshleman, Susan H. ;
Piwowar-Manning, Estelle ;
Wang, Lei ;
Makhema, Joseph ;
Mills, Lisa A. ;
de Bruyn, Guy ;
Sanne, Ian ;
Eron, Joseph ;
Gallant, Joel ;
Havlir, Diane ;
Swindells, Susan ;
Ribaudo, Heather ;
Elharrar, Vanessa ;
Burns, David ;
Taha, Taha E. ;
Nielsen-Saines, Karin ;
Celentano, David ;
Essex, Max ;
Fleming, Thomas R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (06) :493-505
[2]   Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement [J].
Crawford, Keith W. ;
Ripin, David H. Brown ;
Levin, Andrew D. ;
Campbell, Jennifer R. ;
Flexner, Charles .
LANCET INFECTIOUS DISEASES, 2012, 12 (07) :550-560
[3]   Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects [J].
Dooley, Kelly E. ;
Sayre, Patrick ;
Borland, Julie ;
Purdy, Elizabeth ;
Chen, Shuguang ;
Song, Ivy ;
Peppercorn, Amanda ;
Everts, Stephanie ;
Piscitelli, Stephen ;
Flexner, Charles .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (01) :21-27
[4]   Treatment 2.0: catalyzing the next phase of treatment, care and support [J].
Duncombe, Chris ;
Ball, Andrew ;
Passarelli, Carlos ;
Hirnschall, Gottfried .
CURRENT OPINION IN HIV AND AIDS, 2013, 8 (01) :4-11
[5]   Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study [J].
Else, Laura J. ;
Jackson, Akil ;
Puls, Rebekah ;
Hill, Andrew ;
Fahey, Paul ;
Lin, Enmoore ;
Amara, Alieu ;
Siccardi, Marco ;
Watson, Victoria ;
Tjia, John ;
Emery, Sean ;
Khoo, Saye ;
Back, David J. ;
Boffito, Marta .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (03) :1427-1433
[6]   HIV drug development: the next 25 years [J].
Flexner, Charles .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :959-966
[7]   Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America [J].
Genberg, Becky L. ;
Wilson, Ira B. ;
Bangsberg, David R. ;
Arnsten, Julia ;
Goggin, Kathy ;
Remien, Robert H. ;
Simoni, Jane ;
Gross, Robert ;
Reynolds, Nancy ;
Rosen, Marc ;
Liu, Honghu .
AIDS, 2012, 26 (11) :1415-1423
[8]   HIV prevention transformed: the new prevention research agenda [J].
Padian, Nancy S. ;
McCoy, Sandra I. ;
Karim, Salim S. Abdool ;
Hasen, Nina ;
Kim, Julia ;
Bartos, Michael ;
Katabira, Elly ;
Bertozzi, Stefano M. ;
Schwartlaender, Bernhard ;
Cohen, Myron S. .
LANCET, 2011, 378 (9787) :269-278
[9]   Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection [J].
Robertson, Jaime ;
Feinberg, Judith .
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (09) :1363-1375
[10]  
Ruane PJ, 2013, JAIDS-J ACQ IMM DEF, V63, P449, DOI 10.1097/QAI.0b013e3182965d45